AACR 2026
Advancing Next-Generation Oncology: Meet GemPharmatech at AACR 2026
GemPharmatech is excited to attend the AACR Annual Meeting 2026 from April 19 – 22 in San Diego, California, where we will showcase a new generation of preclinical oncology solutions designed to address key challenges in cancer drug development—including therapeutic resistance, tumor heterogeneity, and translational gaps.
Leveraging the world’s largest collection of genetically engineered mouse models (30,000+ strains and growing), we enable researchers to evaluate complex modalities with greater precision and clinical relevance. This year, we spotlight our latest capabilities in in vivo CAR-T, T-cell engagers (TCEs), ADC resistance modeling, and PDX platforms—supporting more predictive and efficient oncology pipelines.
Heading to AACR 2026? Let’s Connect
Visit our booth #3250 to explore our latest research, discover new model capabilities, and connect with our scientific experts. Whether you're advancing early discovery or optimizing preclinical development, we’re here to support your pipeline.
Book a meeting in advance to secure dedicated time with our team.
SCHEDULE A MEETING WITH OUR TEAM →
Explore Our Posters
Our AACR presence grows this year with 15 poster presentations, showcasing the breadth and innovation of our preclinical oncology research. Topics include murine models of bone and brain metastasis, humanized and immune-engrafted mouse platforms, advanced evaluations of CAR-T and TCEs, bispecific antibodies, checkpoint inhibitors, cancer vaccines, and models addressing therapeutic resistance, cancer cachexia, and translational PK predictions.
Connect with our team onsite to discuss how these insights can advance your programs.
Monday, April 20, 2026
09:00 AM - 12:00 PM | Section 27 | Board 12
Poster #2114: Murine models of bone and brain metastasis for preclinical cancer research
09:00 AM - 12:00 PM | Section 29 | Board 16
Poster #2165: An integrated preclinical platform for comprehensive evaluation of T-Cell engagers
09:00 AM - 12:00 PM | Section 29 | Board 17
Poster #2166: Robust in vivo CAR-T efficacy evaluation in a PBMC-reconstituted NCG-MHC-dKO model with delayed GVHD
09:00 AM - 12:00 PM | Section 29 | Board 18
Poster #2167: A novel humanized mouse model for preclinical assessment of anti-CD47 and anti-SIRPΑtherapeutics
02:00 PM - 05:00 PM | Section 27 | Board 18
Poster #3388: One-stop solution for preclinical evaluation of bispecific T-cell engagers targeting STEAP1
02:00 PM - 05:00 PM | Section 27 | Board 19
Poster #3389: Preclinical models for evaluating bispecific antibodies targeting PD-1 and VEGF
02:00 PM - 05:00 PM | Section 27 | Board 20
Poster #3390: Enhanced human immune system engraftment in a novel triple-engineered NCG-hIL6-mTSLP-mFlt3-KOmouse model
02:00 PM - 05:00 PM | Section 27 | Board 21
Poster #3391: The humanized FcRn mouse model: A superior platform for predicting human PK of therapeutic antibodies
02:00 PM - 05:00 PM | Section 27 | Board 22
Poster #3392: Development of novel NCG-hIL15 and hIL-2 mouse models for preclinical assessment of human NK cell function
Tuesday, April 21, 2026
09:00 AM - 12:00 PM | Section 10 | Board 22
Poster #4382: Bridging in vitro screening to in vivo efficacy for cancer vaccines
02:00 PM - 5:00 PM | Section 17 | Board 28
Poster #5859: Novel T cell engager targeting CD3 and CDH17 for the treatment of solid tumors
02:00 PM - 05:00 PM | Section 26 | Board 22
Poster #6076: Preclinical models of cancer cachexia: Bridging the gap to clinical applications
Wednesday, April 22, 2026
09:00 AM - 12:00 PM | Section 30 | Board 10
Poster #7492: Preclinical osimertinib-resistant mouse models for advancing third-generation EGFR-TKI drug development
09:00 AM - 12:00 PM | Section 30 | Board 11
Poster #7493: Novel preclinical models for evaluating checkpoint inhibitor resistance
09:00 AM - 12:00 PM | Section 30 | Board 12
Poster #7494: Development of enhanced enhertu-resistant HER2-positive breast cancer models for ADC resistance research
09:00 AM - 12:00 PM | Section 30 | Board 13
Poster #7495: Modeling of de novo and experimentally induced acquired resistance to trastuzumab deruxtecan in HER2-positive patient-derived xenografts
Advance Your Oncology Research with GemPharmatech
Learn More and Stay Ahead
Explore our latest resources to optimize your oncology research strategy:
On-Demand Webinar
Innovative Mouse Models to Accelerate the Development of In Vivo CAR-T Therapies
Learn how GemPharmatech’s humanized mouse models bridge the CAR-T translational gap—evaluating tumor clearance, CAR persistence, and safety to predict clinical success.
On-Demand Webinar
Overcoming Challenges in the Post-PD-1 Era of Cancer Immunotherapy
Explore strategies to overcome resistance to checkpoint inhibitors, with combination therapies and preclinical models essential for next-generation immunotherapy development.
Blog
Accelerating T-Cell Engager (TCE) Development: Advanced Preclinical Evaluation Solutions
See how advanced preclinical approaches are speeding next-generation TCE therapies to the clinic and revealing the mechanisms behind their efficacy.
Ready to Accelerate Your Pipeline?
With the world’s largest collection of genetically engineered mouse models, GemPharmatech is uniquely positioned to support your oncology research—from discovery to IND-enabling studies.
Meet with us at AACR 2026 to find the right models and strategies for your program.
BOOK A MEETING WITH US TO LEARN MORE →